Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Early Phase 1

1(33.3%)

Phase 3

1(33.3%)

N/A

1(33.3%)

3Total

Early Phase 1(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06713837Phase 3Recruiting

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Role: collaborator

NCT06459024Recruiting

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06831799Completed

ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19

Role: collaborator

NCT06181513Early Phase 1Recruiting

Probiotics in Mild Alzheimer's Disease

Role: collaborator

NCT06436131Not ApplicableCompleted

The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis

Role: collaborator

NCT05799118Recruiting

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Role: lead

NCT06213402Recruiting

RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)

Role: collaborator

NCT05837871Unknown

Genetic and Haematological Modifiers of SCD Severity in Kaduna State, Northern Nigeria

Role: collaborator

All 8 trials loaded